7 results on '"Linda Kievit"'
Search Results
2. Adult Presentation of Noncirrhotic Portal Hypertension and Ascites following Treatment for Wilms’ Tumor in Childhood
- Author
-
Pia Kræmer, Linda Kievit, Henning Grønbæk, and Stephen Hamilton-Dutoit
- Subjects
medicine.medical_specialty ,Cirrhosis ,Portal venous pressure ,Wilms’ tumor ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Esophageal varices ,Case and Review ,Internal medicine ,Ascites ,medicine ,lcsh:RC799-869 ,Portal hypertension ,Vein ,medicine.diagnostic_test ,business.industry ,Wilms' tumor ,medicine.disease ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Liver biopsy ,lcsh:Diseases of the digestive system. Gastroenterology ,030211 gastroenterology & hepatology ,medicine.symptom ,Noncirrhotic portal hypertension ,business - Abstract
A 37-year-old male, who at the age of 8 years had been treated for right-sided Wilms’ tumor with nephrectomy, radiotherapy, and chemotherapy, presented with noncirrhotic portal hypertension (NCPH), grade 2 esophageal varices, and ascites. A CT scan demonstrated hypoplasia of liver segments 2 and 3. A liver biopsy showed portal tract fibrosis without cirrhosis, with histological features of NCPH. Liver vein catheterization showed a normal portal pressure gradient of 5 mm Hg while spleen to hepatic vein pressure was 29 mm Hg. NCPH after therapy for Wilms’ tumor is described in children within the first few years after treatment. This is the first case report in which the patient first presented symptoms as an adult, many years after cancer treatment.
- Published
- 2018
3. 742 DISCONTINUATION OF INFLIXIMAB THERAPY IN PATIENTS WITH CROHN'S DISEASE IN SUSTAINED, COMPLETE CLINICAL-BIOCHEMICAL-ENDOSCOPIC REMISSION: A DOUBLE-BLINDED, PLACEBO-CONTROLLED, RANDOMIZED CLINICAL TRIAL
- Author
-
Svetlana Meisner, Jørgen Jahnsen, Ida Vind, Klaus Bendtzen, Maria Dorn-Rasmussen, Lars Martinsen, Niels Thorsgaard, Sven Almer, Hendrika Adriana Linda Kievit, Jane Moeller, Sine Buhl, Taina Sipponen, Akbar Molazahi, Eva E. Dahl, Jens Kjeldsen, Mark A. Ainsworth, Katrine R. Christensen, Casper Steenholdt, Jens Frederik Dahlerup, Jan Marsal, Synn⊘ve L. Aure, J⊘rn Brynskov, Ole Østergaard Thomsen, Natalia Pedersen, Tobias Wirenfeldt Klausen, J⊘rgen Steen Agnholt, and Annett G. Cannon
- Subjects
medicine.medical_specialty ,education.field_of_study ,Crohn's disease ,Hepatology ,business.industry ,Population ,Gastroenterology ,medicine.disease ,Placebo ,Infliximab ,Discontinuation ,law.invention ,Maintenance therapy ,Randomized controlled trial ,law ,Internal medicine ,Multicenter trial ,medicine ,education ,business ,medicine.drug - Abstract
Background It remains unknown whether infliximab (IFX) successfully can be discontinued once Crohn's disease (CD) patients have attained sustained, complete clinical, biochemical, and endoscopic remission. No randomized, placebo (PBO) controlled trial has previously assessed this. Methods This double-blind, randomized, PBO-controlled multicenter trial enrolled patients with luminal CD who had been treated with standard IFX maintenance therapy for at least 1 year, in complete remission at the time of inclusion defined as CD Activity Index (CDAI) 150 with an increase in CDAI >70-point from baseline over two consecutive weeks; or definitive clinical relapse requiring immediate intervention as judged by treating physician) in the intention-to-treat population. Results The study population comprised 115 patients (n=54 female; age median 34 years [IQR 26-50]; disease duration median 6 years [3-12]; IFX treatment duration median 23 months [16-39]). All patients were in combined clinical- (CDAI median 41 [IQR 15-66]), biochemical- (CRP median 3mg/L [IQR 2-4]), and endoscopic- (Simple Endoscopic Score for CD median 0, [IQR 0-0] (n=99)) remission. Patients were randomized to continued IFX therapy (n=59) or to start PBO infusions (n=56) (Figure 1). Time to relapse was significantly shorter among patients who discontinued IFX as compared to those continuing IFX (p 150) the figures were 47% in the PBO group vs. 98% in IFX group (p Conclusion This first double-blinded placebo-controlled RCT of IFX withdrawal in Crohn's disease patients strongly suggests that discontinuation of IFX leads to a considerable risk of relapse despite combined clinical, biochemical, and endoscopic remission. Download : Download high-res image (53KB) Download : Download full-size image Download : Download high-res image (56KB) Download : Download full-size image
- Published
- 2021
4. Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort-An Epi-IBD Study
- Author
-
Selwyn Odes, Riina Salupere, Pekka Collin, Konstantinos H. Katsanos, Dana Duricova, Hendrika Adriana Linda Kievit, I. Kaimakliotis, Jóngerð Midjord, Dimitrios K. Christodoulou, Johan Burisch, Carl Eriksson, Luísa Castro, Ebbe Langholz, Vibeke Andersen, Jonas Halfvarson, Pierre Ellul, Naila Arebi, Pia Oksanen, Pia Munkholm, Shaji Sebastian, K R Nielsen, Elena Belousova, Renata D'Incà, Inna Nikulina, Jens Kjeldsen, Marko Brinar, Limas Kupčinskas, Vicent Hernandez, Gediminas Kiudelis, Karina Winther Andersen, Zsuzsanna Vegh, Alina Toca, Corinne Gower-Rousseau, Svetlana Turcan, Martin Bortlik, Adrian Goldis, Natalia Pedersen, Mathurin Fumery, Peter L. Lakatos, Fernando Magro, Silvija Čuković-Čavka, Ravi Misra, Stefania Chetcuti Zammit, Doron Schwartz, D. Valpiani, Luísa Barros, Sally Myers, University of Copenhagen = Københavns Universitet (UCPH), University Hospital of Ioannina, Centro Hospitalar Universitário de São João [Porto], Universidade do Porto = University of Porto, Odense University Hospital (OUH), Semmelweis University [Budapest], McGill University Health Center [Montreal] (MUHC), Örebro University, CHU Amiens-Picardie, Registre EPIMAD, CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Amiens-Picardie-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service d'Epidémiologie et de Santé Publique [Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), University Hospital Centre Zagreb, Partenaires INRAE, University of Zagreb, Moscow Regional Research Clinical Institute (MONICA), Hull and East Yorkshire Eye Hospital, Lithuanian University of health Sciences [Kaunas], Ben-Gurion University of the Negev (BGU), G.B. Morgagni-Pierantoni Hospital [Forlì, Italy], Università degli Studi di Padova = University of Padua (Unipd), University of Tartu, Mater Dei Hospital [Malta], ISCARE, Charles University [Prague] (CU), Victor Babeş University of Medicine and Pharmacy (UMFT), University research clinic [Herning, Denmark], State University of Moldova, National Hospital of the Faroe Islands [Tórshavn, Faroe Islands], Viborg Hospital, Regional Hospital West Jutland [Denmark], University of Southern Denmark (SDU), St Mark's Hospital, Tampere University Hospital, University of Tampere [Finland], and Instituto de Investigación Sanitaria Galicia Sur [Vigo, Spain]
- Subjects
Adult ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,[SDV]Life Sciences [q-bio] ,Population ,Inflammatory bowel disease ,surgery ,03 medical and health sciences ,0302 clinical medicine ,Gastrointestinal Agents ,Internal medicine ,medicine ,Humans ,Immunologic Factors ,biologics ,Prospective Studies ,Prospective cohort study ,education ,Colectomy ,education.field_of_study ,treatment ,business.industry ,hospitalisation ,Hazard ratio ,Gastroenterology ,General Medicine ,Middle Aged ,medicine.disease ,Ulcerative colitis ,Europe ,Hospitalization ,030220 oncology & carcinogenesis ,Cohort ,Disease Progression ,030211 gastroenterology & hepatology ,Colitis, Ulcerative ,Female ,prognosis ,business ,Cohort study ,Follow-Up Studies - Abstract
Background and Aims: Few population-based cohort studies have assessed the disease course of ulcerative colitis [UC] in the era of biological therapy and widespread use of immunomodulators. The aim of this study was to assess the 5-year outcome and disease course of patients with UC in the Epi-IBD cohort.Methods: In a prospective, population-based inception cohort of unselected patients with UC, patients were followed up from the time of their diagnosis, which included the collection of their clinical data, demographics, disease activity, medical therapy, and rates of surgery, cancers, and deaths. Associations between outcomes and multiple covariates were analysed by Cox regression analysis.Results: A total of 717 patients were included in the study. During follow-up, 43 [6%] patients underwent a colectomy and 163 [23%] patients were hospitalised. Of patients with limited colitis [distal to the left flexure], 90 [21%] progressed to extensive colitis. In addition, 92 [27%] patients with extensive colitis experienced a regression in disease extent, which was associated with a reduced risk of hospitalisation (hazard ratio [HR]: 0.5 95% CI: 0.3-0.8]. Overall, patients were treated similarly in both geographical regions; 80 [11%] patients needed biological therapy and 210 [29%] patients received immunomodulators. Treatment with immunomodulators was found to reduce the risk of hospitalisation [HR: 0.5 95% CI: 0.3-0.8].Conclusions: Although patients in this population-based cohort were treated more aggressively with immunomodulators and biological therapy than in cohorts from the previous two decades, their disease outcomes, including colectomy rates, were no different. However, treatment with immunomodulators was found to reduce the risk of hospitalisation.
- Published
- 2018
5. OP15 Cost analysis in a prospective European population-based inception cohort: is there a cost-saving effect of biological therapy?
- Author
-
Svetlana Turcan, Ebbe Langholz, Pia Oksanen, Zeljko Krznaric, Elena Belousova, D. Valpiani, I. Kaimakliotis, Limas Kupčinskas, Naila Arebi, Pia S. Munkholm, Vibeke Andersen, Péter Lakatos, Niels C Pedersen, Epi-IBD, Hillel Vardi, Shmuel Odes, K.H. Katsanos, K R Nielsen, Zsuzsanna Vegh, Renata D'Incà, Shaji Sebastian, Dana Duricova, Dagan Schwartz, Johan Burisch, Jonas Halfvarson, Jens Frederik Dahlerup, Pierre Ellul, Riina Salupere, Mathurin Fumery, Hendrika Adriana Linda Kievit, Fernando Magro, Adrian Goldis, Vicent Hernandez, and M. Giannotta
- Subjects
0301 basic medicine ,business.industry ,Gastroenterology ,General Medicine ,European population ,INCEPTION COHORT ,Cost savings ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Environmental health ,Cost analysis ,Medicine ,030211 gastroenterology & hepatology ,business ,health care economics and organizations - Abstract
Cost analysis in a prospective European population-based inception cohort : is there a cost-saving effect of biological therapy?
- Published
- 2019
6. Su1316 Unchanged Surgery and Hospitalization Rates in an East-West European Inception Cohort Despite Differences in Use of Biologicals - 3-Year Follow-Up of the ECCO-EpiCom Cohort
- Author
-
K R Nielsen, Adrian Goldis, Epameinondas V. Tsianos, Zsuzsanna Vegh, Svetlana Turcan, Ebbe Langholz, Riina Salupere, Selwyn Odes, Pia S. Munkholm, Fernando Magro, John Kaimakliotis, Linda Kievit, Vicent Hernandez, Dana Duricova, Jens Frederik Dahlerup, Peter L. Lakatos, Johan Burisch, Pia Manninen, Naila Arebi, Jonas Halfvarson, Limas Kupčinskas, and Renata D'Incà
- Subjects
medicine.medical_specialty ,Pediatrics ,Hepatology ,East west ,business.industry ,Cohort ,Gastroenterology ,medicine ,Inflammatory Bowel Diseases ,business ,INCEPTION COHORT ,Surgery ,Cohort study - Published
- 2015
7. Adult Presentation of Noncirrhotic Portal Hypertension and Ascites following Treatment for Wilms' Tumor in Childhood.
- Author
-
Kievit, Linda, Kræmer, Pia, Hamilton-Dutoit, Stephen, and Grønbæk, Henning
- Subjects
ASCITES ,PORTAL hypertension ,NEPHROBLASTOMA - Abstract
A 37-year-old male, who at the age of 8 years had been treated for right-sided Wilms' tumor with nephrectomy, radiotherapy, and chemotherapy, presented with noncirrhotic portal hypertension (NCPH), grade 2 esophageal varices, and ascites. A CT scan demonstrated hypoplasia of liver segments 2 and 3. A liver biopsy showed portal tract fibrosis without cirrhosis, with histological features of NCPH. Liver vein catheterization showed a normal portal pressure gradient of 5 mm Hg while spleen to hepatic vein pressure was 29 mm Hg. NCPH after therapy for Wilms' tumor is described in children within the first few years after treatment. This is the first case report in which the patient first presented symptoms as an adult, many years after cancer treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.